Niagen Bioscience, Inc. financial data

Symbol
NAGE on Nasdaq
Location
10900 Wilshire Blvd, Suite 600, Los Angeles, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 382 % +44.7%
Quick Ratio 63.9 % -1.5%
Debt-to-equity 43.6 % -45%
Return On Equity 34.6 % +613%
Return On Assets 24.1 % +790%
Operating Margin 15.5 % +3074%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79.8M shares +4.48%
Common Stock, Shares, Outstanding 79.6M shares +4.75%
Entity Public Float 143M USD +76%
Common Stock, Value, Issued 79K USD +3.95%
Weighted Average Number of Shares Outstanding, Basic 79.8M shares +5.01%
Weighted Average Number of Shares Outstanding, Diluted 86.6M shares +11.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 125M USD +36%
Cost of Revenue 45M USD +27.4%
Research and Development Expense 5.94M USD +1.28%
Selling and Marketing Expense 33.8M USD +24%
General and Administrative Expense 20.6M USD -9.28%
Operating Income (Loss) 19.3M USD +4219%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 21.3M USD +156%
Income Tax Expense (Benefit) 823K USD
Net Income (Loss) Attributable to Parent 20.4M USD +1276%
Earnings Per Share, Basic 0 USD/shares +2700%
Earnings Per Share, Diluted 0 USD/shares +2400%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 64.1M USD +99.1%
Accounts Receivable, after Allowance for Credit Loss, Current 8.51M USD +19.9%
Inventory, Net 18.8M USD +78.2%
Assets, Current 93.6M USD +79.6%
Operating Lease, Right-of-Use Asset 2.36M USD +24.3%
Intangible Assets, Net (Excluding Goodwill) 246K USD -38%
Other Assets, Noncurrent 417K USD +11.5%
Assets 98.1M USD +73.6%
Accounts Payable, Current 12.7M USD +84.6%
Accrued Liabilities, Current 8.7M USD -9.3%
Liabilities, Current 22.7M USD +28.3%
Contract with Customer, Liability, Noncurrent 2.67M USD +3.68%
Operating Lease, Liability, Noncurrent 2.08M USD +10.9%
Liabilities 27.5M USD +24%
Retained Earnings (Accumulated Deficit) -169M USD +10.8%
Stockholders' Equity Attributable to Parent 70.7M USD +106%
Liabilities and Equity 98.1M USD +73.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 7.88M USD +2572%
Net Cash Provided by (Used in) Financing Activities 3.11M USD
Net Cash Provided by (Used in) Investing Activities -32K USD +22%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 79.6M shares +4.75%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11M USD +4465%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 64.3M USD +98.4%
Deferred Tax Assets, Valuation Allowance 44.3M USD -4.53%
Deferred Tax Assets, Gross 44.7M USD -4.43%
Operating Lease, Liability 3.05M USD +5.97%
Depreciation 158K USD -11.2%
Lessee, Operating Lease, Liability, to be Paid 3.44M USD +9.74%
Operating Lease, Liability, Current 976K USD -3.18%
Lessee, Operating Lease, Liability, to be Paid, Year Two 782K USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.18M USD +4.23%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +15.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 385K USD +52.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 657K USD +33.8%
Deferred Tax Assets, Operating Loss Carryforwards 35.2M USD -4.11%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 338K USD -5.59%
Operating Lease, Payments 295K USD +224%
Additional Paid in Capital 239M USD +7.11%
Amortization of Intangible Assets 37K USD -2.63%
Deferred Tax Assets, Net of Valuation Allowance 386K USD +7.82%